Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

Frontline Treatments for Follicular Lymphoma

Insights From:Jennifer R. Brown, MD, PhD, Harvard Medical School; Richard R. Furman, MD, Weill Cornell Medical College; Brad S. Kahl, MD, UW Carbone Cancer Cente
Published: Wednesday, Sep 30, 2015

 
Assessing symptoms is the first step when approaching a patient with newly diagnosed follicular lymphoma, states Brad S. Kahl, MD. Some individuals with follicular lymphoma remain asymptomatic and may be a candidate for a watch-and-wait strategy, where treatment is not needed immediately. Tumor burden is assessed via computerized tomography or positron emission tomography imaging to determine whether to defer or begin treatment.
 
First-line treatment is typically a combination of bendamustine and rituximab, says Kahl, which is a well-tolerated regimen for most patients. Dose reductions of bendamustine may be needed for older patients who have reduced creatinine clearance, notes Kahl. Two years of maintenance therapy with rituximab is often recommended. Although maintenance therapy can prolong the duration of remission or progression-free survival, it has not been shown to have an impact on overall survival, comments Kahl.
 
Long-term data are needed to determine whether there is a difference in these regimens in terms of adverse effects, such as secondary myelodysplastic syndromes, acute myeloid leukemia, or disease transformation. Transformation from a low-grade follicular lymphoma to an aggressive lymphoma can be very problematic, says Richard R. Furman, MD.

Newer regimens that avoid chemotherapy, such as combination therapy with lenalidomide and rituximab, afford an opportunity to effectively control the disease for long periods of time without toxicity, comments Furman. If patients progress on lenalidomide and rituximab, there is still an opportunity to manage their disease at that point in time with chemotherapy.
 
Slider Left
Slider Right

 
Assessing symptoms is the first step when approaching a patient with newly diagnosed follicular lymphoma, states Brad S. Kahl, MD. Some individuals with follicular lymphoma remain asymptomatic and may be a candidate for a watch-and-wait strategy, where treatment is not needed immediately. Tumor burden is assessed via computerized tomography or positron emission tomography imaging to determine whether to defer or begin treatment.
 
First-line treatment is typically a combination of bendamustine and rituximab, says Kahl, which is a well-tolerated regimen for most patients. Dose reductions of bendamustine may be needed for older patients who have reduced creatinine clearance, notes Kahl. Two years of maintenance therapy with rituximab is often recommended. Although maintenance therapy can prolong the duration of remission or progression-free survival, it has not been shown to have an impact on overall survival, comments Kahl.
 
Long-term data are needed to determine whether there is a difference in these regimens in terms of adverse effects, such as secondary myelodysplastic syndromes, acute myeloid leukemia, or disease transformation. Transformation from a low-grade follicular lymphoma to an aggressive lymphoma can be very problematic, says Richard R. Furman, MD.

Newer regimens that avoid chemotherapy, such as combination therapy with lenalidomide and rituximab, afford an opportunity to effectively control the disease for long periods of time without toxicity, comments Furman. If patients progress on lenalidomide and rituximab, there is still an opportunity to manage their disease at that point in time with chemotherapy.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x